Vonoprazan's clinical development pipeline extends beyond the approved H. pylori and erosive esophagitis indications toward additional acid-related and non-acid gastrointestinal applications, with the Vonoprazan Fumarate API Market reflecting the indication expansion programs that could substantially increase vonoprazan API demand beyond the current commercial volume. Vonoprazan in...